Array BioPharma sees success in clinical trials
BOULDER — Array BioPharma (Nasdaq: ARRY) experienced stock prices up 7 percent before the market opened following the announcement of positive data from clinical trials.
The third phase of clinical trials of its drug binimetinib combined with encorafenib showed positive results in patients with metastatic melanoma.
Earlier this summer, Array filed new drug applications to the Food and Drug Administration for the combination of the two drugs.
SPONSORED CONTENT
Exploring & expressing grief
Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.
At the time of publication, Array’s stock slid slightly, dropping from $11.82 when the market opened to $10.53 per share.
BOULDER — Array BioPharma (Nasdaq: ARRY) experienced stock prices up 7 percent before the market opened following the announcement of positive data from clinical trials.
The third phase of clinical trials of its drug binimetinib combined with encorafenib showed positive results in patients with metastatic melanoma.
Earlier this summer, Array filed new drug applications to the Food and Drug Administration for the combination of the two drugs.
At the time of publication, Array’s stock slid slightly, dropping from $11.82 when the market opened to $10.53 per share.
…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
